3D HucMSCs derived extracellular vesicles enhanced therapeutic efficacy in treating intrauterine adhesions via BECN1 delivery
Peng J., Zhang J., Li Q., Liu W., Zou W., Zhu L.
Laboratory Study, published in Mater Today Bio (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Mater Today Bio (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 42256061
- PMCID
- PMC13241656
- DOI
- 10.1016/j.mtbio.2026.103276
Abstract (original English)
Intrauterine adhesion (IUA) is a significant cause of female infertility and a critical public health concern among women of childbearing age. Emerging evidence has highlighted the therapeutic potential of mesenchymal stem cell-derived extracellular vesicles (EVs) in IUA treatment. However, conventional two-dimensional (2D) culture systems impose constraints on the yield and biological activity of EVs. In this study, we employed a three-dimensional (3D) culture platform based on gelatin methacrylate (GelMA) microspheres to culture human umbilical cord mesenchymal stem cells and isolate MSC-EVs. Comparative analysis demonstrated that 3D-EVs exhibited significantly superior therapeutic effects on restoring the proliferation, migration, viability, and alleviating fibrosis of mifepristone-injured human endometrial stromal cells (hESCs) compared with 2D-EVs in vitro . In IUA animal models, in situ treatment with GelMA-encapsulated 3D-EVs exhibited remarkable regenerative capabilities. The treatment effectively rejuvenated endometrial structure including mucosal thickness and glandular density, ameliorated endometrial fibrosis, and ultimately improved reproductive outcomes. Results from proteomic profiling and functional verification assays revealed that elevated expression of BECN1 in 3D-EVs contributes to the enhanced therapeutic effect of 3D-EVs on injured hESCs. This study establ
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.